BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 16216001)

  • 1. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients.
    Marchi E; Alinari L; Tani M; Stefoni V; Pimpinelli N; Berti E; Pagano L; Bernengo MG; Zaja F; Rupoli S; Pileri S; Baccarani M; Zinzani PL
    Cancer; 2005 Dec; 104(11):2437-41. PubMed ID: 16216001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients.
    Zinzani PL; Baliva G; Magagnoli M; Bendandi M; Modugno G; Gherlinzoni F; Orcioni GF; Ascani S; Simoni R; Pileri SA; Tura S
    J Clin Oncol; 2000 Jul; 18(13):2603-6. PubMed ID: 10893292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients.
    Zinzani PL; Magagnoli M; Bendandi M; Orcioni GF; Gherlinzoni F; Albertini P; Pileri SA; Tura S
    Ann Oncol; 1998 Dec; 9(12):1351-3. PubMed ID: 9932168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma.
    Duvic M; Talpur R; Wen S; Kurzrock R; David CL; Apisarnthanarax N
    Clin Lymphoma Myeloma; 2006 Jul; 7(1):51-8. PubMed ID: 16879770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome.
    Zinzani PL; Venturini F; Stefoni V; Fina M; Pellegrini C; Derenzini E; Gandolfi L; Broccoli A; Argnani L; Quirini F; Pileri S; Baccarani M
    Ann Oncol; 2010 Apr; 21(4):860-863. PubMed ID: 19887465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Gemcitabine Monotherapy for Advanced Mycosis Fungoides--Two Case Reports and a Literature Review].
    Masuzawa M; Takasu H; Amoh Y
    Gan To Kagaku Ryoho; 2015 Dec; 42(13):2451-5. PubMed ID: 26809303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous low-dose gemcitabine in primary cutaneous T cell lymphoma: A retrospective study.
    Di Raimondo C; Vaccarini S; Nunzi A; Rapisarda V; Zizzari A; Meconi F; Monopoli A; Narducci MG; Scala E; Bianchi L; Tesei C; Cantonetti M
    Dermatol Ther; 2022 Jun; 35(6):e15482. PubMed ID: 35373414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma.
    Illidge T; Chan C; Counsell N; Morris S; Scarisbrick J; Gilson D; Popova B; Patrick P; Smith P; Whittaker S; Cowan R
    Br J Cancer; 2013 Nov; 109(10):2566-73. PubMed ID: 24136145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Outcomes of Advanced-Stage Cutaneous Lymphoma under Low-Dose Gemcitabine Treatment: Real-Life Data from the German Cutaneous Lymphoma Network.
    Blazejak C; Stranzenbach R; Gosman J; Gambichler T; Wehkamp U; Stendel S; Klemke CD; Wobser M; Olk J; Nicolay JP; Weyermann M; Stadler R; Assaf C
    Dermatology; 2022; 238(3):498-506. PubMed ID: 34474414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine treatment in cutaneous T-cell lymphoma: a multicentre study of 23 cases.
    Jidar K; Ingen-Housz-Oro S; Beylot-Barry M; Paul C; Chaoui D; Sigal-Grinberg M; Morel P; Dubertret L; Bachelez H
    Br J Dermatol; 2009 Sep; 161(3):660-3. PubMed ID: 19438862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine.
    Pellegrini C; Stefoni V; Casadei B; Maglie R; Argnani L; Zinzani PL
    Ann Hematol; 2014 Nov; 93(11):1853-7. PubMed ID: 24908331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial.
    Oh SY; Kim WS; Lee DH; Kim SJ; Kim SH; Ryoo BY; Kang HJ; Choi YJ; Chung JS; Kim HJ; Suh C
    Invest New Drugs; 2010 Apr; 28(2):171-7. PubMed ID: 19421710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycosis fungoides and Sezary syndrome: therapeutic approach and outcome in 113 patients.
    Anadolu RY; Birol A; Sanli H; Erdem C; Türsen U
    Int J Dermatol; 2005 Jul; 44(7):559-65. PubMed ID: 15985024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma.
    Duvic M; Apisarnthanarax N; Cohen DS; Smith TL; Ha CS; Kurzrock R
    J Am Acad Dermatol; 2003 Jul; 49(1):35-49. PubMed ID: 12833006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients.
    Zinzani PL; Bendandi M; Stefoni V; Albertini P; Gherlinzoni F; Tani M; Piccaluga PP; Tura S
    Haematologica; 2000 Sep; 85(9):926-9. PubMed ID: 10980630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective phase II study of single-agent gemcitabine in untreated elderly patients with stage IIIB/IV non-small-cell lung cancer.
    Martoni A; Di Fabio F; Guaraldi M; Piana E; Ramini R; Lelli G; Palomba G; Artioli F; Bandieri E; Robustelli Della Cuna G; Preti P
    Am J Clin Oncol; 2001 Dec; 24(6):614-7. PubMed ID: 11801766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial.
    Van Kooten M; Traine G; Cinat G; Cazap E; Comba AZ; Vicente H; Sena S; Nievas OR; Orlando M
    Br J Cancer; 1999 Nov; 81(5):846-9. PubMed ID: 10555756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
    Olsen EA; Kim YH; Kuzel TM; Pacheco TR; Foss FM; Parker S; Frankel SR; Chen C; Ricker JL; Arduino JM; Duvic M
    J Clin Oncol; 2007 Jul; 25(21):3109-15. PubMed ID: 17577020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
    Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
    Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
    Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
    Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.